EP300 and cancer: Three patients’ cancers (50%; patients 1, 5, and 6) had variants of unknown significance (VUS) in DNA repair and chromatin remodeling genes, namely base substitutions, INDELs (insertions or the deletion of multiple bases), or truncations, of unknown functional significance in breast cancer 2, early onset (BRCA2), Fanconi anemia complementation group (FANCF), SET domain containing 2 (SETD2), poly (ADP-ribose) polymerase 1 (PARP1), nuclear receptor corepressor 1 (NCOR1), core-binding factor subunit b (CBFB), and E1A binding protein 300 (EP300).